Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (met-HeFT)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Incidence of infective endocarditis during the coronavirus disease 2019 pandemic: A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Henrik Wiggers
  • Lars Køber
  • Gunnar Gislason
  • Morten Schou
  • Mikael Kjær Poulsen
  • Søren Vraa
  • Olav Wendelbo Nielsen
  • Niels Eske Bruun
  • Helene Nørrelund
  • Malene Hollingdal
  • Anders Barasa
  • Morten Bøttcher
  • Karen Dodt
  • Vibeke Brogaard Hansen
  • Gitte Nielsen
  • Anne Sejr Knudsen
  • Jens Lomholdt
  • Kirsten Vilain Mikkelsen
  • Bartlomiej Jonczy
  • Jens Brønnum-Schou
  • Monica Petronela Poenaru
  • Jawdat Abdulla
  • Ilan Raymond
  • Kiomars Mahboubi
  • Karen Sillesen
  • Kristine Serup-Hansen
  • Jette Sandberg Madsen
  • Søren Lund Kristensen
  • Anders Hostrup Larsen
  • Hans Erik Bøtker
  • Christian Torp-Petersen
  • Hans Eiskjær
  • Jacob Møller
  • Christian Hassager
  • Flemming Hald Steffensen
  • Bo Martin Bibby
  • Jens Refsgaard
  • Dan Eik Høfsten
  • Søren Mellemkjær
  • Finn Gustafsson
View graph of relations

OBJECTIVES: The DANHEART trial is a multicenter, randomized (1:1), parallel-group, double-blind, placebo-controlled study in chronic heart failure patients with reduced ejection fraction (HFrEF). This investigator driven study will include 1500 HFrEF patients and test in a 2 x 2 factorial design: 1) if hydralazine-isosorbide dinitrate reduces the incidence of death and hospitalization with worsening heart failure vs. placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs. placebo in patients with diabetes or prediabetes (Met-HeFT).

METHODS: Symptomatic, optimally treated HFrEF patients with LVEF ≤40% are randomized to active vs. placebo treatment. Patients can be randomized in either both H-HeFT and Met-HeFT or to only one of these study arms. In this event-driven study, it is anticipated that 1300 patients should be included in H-HeFT and 1100 in Met-HeFT and followed for an average of 4years.

RESULTS: As of May 2020, 296 patients have been randomized at 20 centers in Denmark.

CONCLUSION: The H-HeFT and Met-HeFT studies will yield new knowledge about the potential benefit and safety of two commonly prescribed drugs with limited randomized data in patients with HFrEF.

Original languageEnglish
JournalAmerican Heart Journal
ISSN0002-8703
DOIs
Publication statusE-pub ahead of print - 8 Oct 2020

ID: 61009432